Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy

被引:16
|
作者
Xiao, Yuchen [1 ,2 ]
Zhu, Tianchuan [1 ]
Zeng, Qi [3 ]
Tan, Qingqin [1 ]
Jiang, Guanmin [4 ]
Huang, Xi [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Infect & Immun, Guangdong Prov Key Lab Biomed Imaging, Zhuhai 519000, Guangdong, Peoples R China
[2] Southern Marine Sci & Engn Guangdong Lab, Zhuhai 519000, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Oncol, Zhuhai 519000, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Clin Lab, Zhuhai 519000, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
PD-L1; Photothermal ablation; Biomimetic nanoparticles; Tumor microenvironment; Colorectal cancer; RESISTANCE;
D O I
10.1016/j.actbio.2022.11.043
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand pro-grammed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, including colorectal cancer. However, the efficacy of PD-1/PD-L1 inhibitors is limited in some colorec-tal cancers within the immunosuppressive tumor microenvironment (such as when there is a lack of immune cell infiltration). Herein, anti-PD-L1 functionalized biomimetic polydopamine-modified gold nanostar nanoparticles (PDA/GNS@aPD-L1 NPs) were developed for synergistic anti-tumor treatment by combining PD-1/PD-L1 blockade with photothermal ablation. PDA/GNS@aPD-L1 NPs were prepared by encapsulating photothermal nanoparticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane isolated from anti-PD-L1 single-chain variable fragment (scFv) over-expressing cells. In ad-dition to disrupting PD-1/PD-L1 immunosuppressive signals, the anti-PD-L1 scFv on the membrane of PDA/GNS@aPD-L1 NPs was conducive to the accumulation of PDA-GNS at tumor sites. Importantly, the tu-mor photothermal ablation induced by PDA-GNS could reverse the immunosuppressive tumor microenvi-ronment, thereby further improving the efficiency of PD-1/PD-L1 blockade therapy. In this study, the syn-thetized PDA/GNS@aPD-L1 NPs exhibited good biocompatibility, efficient photothermal conversion ability, and enhanced tumor-targeting ability. In vivo studies revealed that a PDA/GNS@aPD-L1 NP-based thera-peutic strategy significantly inhibited tumor growth, and prolonged overall survival by further promot-ing the maturation of dendritic cells (DCs), increasing the infiltration of CD8 + T cells, and decreasing the number of immunosuppressive cells (such as regulatory T cells and myeloid-derived suppressive cells). Collectively, the developed PDA/GNS@aPD-L1 NP-based therapeutic strategy combines PD-1/PD-L1 block-ade with photothermal ablation, which could remodel the tumor microenvironment for effective clinical colorectal cancer therapy.Statement of significance Immunosuppressive tumor microenvironment is the main challenge facing programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade therapy. By encapsulating photothermal nanopar-ticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane over-expressing anti-PD -L1 single-chain variable fragment, we constructed anti-PD-L1 functionalized biomimetic nanoparticles (PDA/GNS@aPD-L1 NPs). By specific binding to the PD-L1 present on tumor cells, PDA/GNS@aPD-L1 NPs could disrupt PD-1/PD-L1 immunosuppression signaling, and effectively deliver PDA-GNS targeting to tu-mor sites. Additionally, PDA-GNS-mediated local photothermal ablation of tumors promoted the release of tumor-associated antigens and thus activated anti-tumor immune responses. Meanwhile, hyperthermia facilitates immune cell infiltration by increasing tumor vascular permeability. Therefore, PDA/GNS@aPD-L1 NPs could sensitize tumors to PD-1/PD-L1 blockade therapy by remodeling the immunosuppressive tumor microenvironment, which provides a new strategy for tumor treatment.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:451 / 466
页数:16
相关论文
共 50 条
  • [41] Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
    Jiang, Yao
    Hong, Kai
    Zhao, Yingchao
    Xu, Kai
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
    Iafolla, Marco A. J.
    Juergens, Rosalyn A.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [43] Programmed death-1 blockade in mismatch repair deficient colorectal cancer.
    Le, Dung T.
    Uram, Jennifer N.
    Wang, Hao
    Bartlett, Bjarne
    Kemberling, Holly
    Eyring, Aleksandra
    Azad, Nilofer Saba
    Laheru, Dan
    Donehower, Ross C.
    Crocenzi, Todd S.
    Goldberg, Richard M.
    Fisher, George A.
    Lee, James J.
    Greten, Tim F.
    Koshiji, Minori
    Kang, SoonMo Peter
    Anders, Robert A.
    Eshleman, James R.
    Vogelstein, Bert
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
    Ohigashi, Y
    Sho, M
    Yamada, Y
    Tsurui, Y
    Hamada, K
    Ikeda, N
    Mizuno, T
    Yoriki, R
    Kashizuka, H
    Yane, K
    Tsushima, F
    Otsuki, N
    Yagita, H
    Azuma, M
    Nakajima, Y
    CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2947 - 2953
  • [45] Correction to: Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review
    Caleb J. Smith
    Yahya Almodallal
    Aminah Jatoi
    Current Oncology Reports, 2021, 23
  • [46] Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
    Nomi, Takeo
    Sho, Masayuki
    Akahori, Takahiro
    Hamada, Kaoru
    Kubo, Atsushi
    Kanehiro, Hiromichi
    Nakamura, Shinji
    Enomoto, Koji
    Yagita, Hideo
    Azuma, Miyuki
    Nakajima, Yoshiyuki
    CLINICAL CANCER RESEARCH, 2007, 13 (07) : 2151 - 2157
  • [47] Plasma levels of soluble programmed death-1 and programmed death-ligand 1 in the patients with autoimmune hepatitis and primary biliary cholangitis
    Jang, Boo-Ok
    Choi, Jae Kyun
    Choi, Gwang Hyeon
    Jeong, Sook-Hyang
    Jang, Eun Sun
    Kim, Jin-Wook
    Kim, Si Ho
    Lee, Kyunghan
    Choi, Yun Suk
    Jeong, Da Woon
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 355 - 355
  • [48] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    LABORATORY INVESTIGATION, 2017, 97 : 344A - 344A
  • [49] Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege
    Cheng, Xuyang
    Dai, Hehua
    Wan, Ni
    Moore, Yolonda
    Vankayalapati, Ramakrishna
    Dai, Zhenhua
    TRANSPLANTATION, 2009, 87 (12) : 1778 - 1786
  • [50] Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights
    Schalper, Kurt A.
    Venur, Vyshak Alva
    Velcheti, Vamsidhar
    JOURNAL OF RECEPTOR LIGAND AND CHANNEL RESEARCH, 2015, 8 : 1 - 7